Compare Bristol-Myers Squibb Co (BMY) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs The Coca-Cola Co K — how do they compare? Bristol-Myers Squibb Co trades at $57.13 (market cap $116.30B), while The Coca-Cola Co K trades at $83.29 (market cap $357.45B). The key difference: The Coca-Cola Co K is far larger — about 3.1× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | KO | |
|---|---|---|
Market Cap | $116.30B | $357.45B |
Sector | Health | Consumer Staples |
52-Week High | $62.37 | $84.25 |
52-Week Low | $42.60 | $65.67 |
Enterprise Value | $152.24B | $387.52B |
Dividend Yield | 4.42% | 2.55% |
Volume | — | 14,630,257 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Coca-Cola (KO) trades at $84.25, up 0.91% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 27.8% net margin and 45.8% ROE, though valuation multiples like P/E of 26.5 appear elevated. Recent news highlights institutional buying and stable demand trends ahead of Q2 earnings.
The outlook remains positive with a $89.75 analyst target suggesting 6.5% upside, supported by dividend reliability. Key risks include high debt levels and regional demand volatility. The stock presents a steady growth opportunity with moderate upside potential balanced by valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
